Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jul;240(1):89-94.
doi: 10.1097/01.sla.0000129492.95311.f2.

Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma

Yi-Yin Jan  1 , Ta-Sen Yeh, Jun-Nan Yeh, Horng-Ren Yang, Miin-Fu Chen
Affiliations

Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma

Yi-Yin Jan et al. Ann Surg. 2004 Jul.

Abstract

Objective: We sought to determine the expression of molecular markers in an animal model of cholangiocarcinoma compared with those in human cholangiocarcinoma.

Summary background data: Cholangiocarcinoma is a rare disease characterized by early intrahepatic and extrahepatic spread, which seriously limits the efficacy of surgery. Establishing an experimental model to study the cholangiocarcinogenesis is desirable.

Methods: Sprague-Dawley rats weighing 300 +/- 50 g were used for the study group. The animals were given 0.3% thioacetamide in tap water continuously. Thirty mass-forming peripheral cholangiocarcinoma patients also were studied. Expression of epidermal growth factor receptor (EGFR), MUC1, MUC2, MUC5AC, MMP-2, MMP-9, and p53 in both human and experimental rat cholangiocarcinoma was examined using immunohistochemistry.

Results: Using thioacetamide 0.3% as a hepatoxin to induce cholangiocarcinoma in rats, microfoci of cancerous cells were detected from 12 weeks, and all experimental rats displayed diffuse mass-forming cholangiocarcinoma after 24 weeks. EGFR was strongly expressed in 14 (47%) of 30 human cholangiocarcinoms and 24 (100%) of 24 rat cholangiocarcinomas, respectively. MUC1 was strongly expressed in all human and rat cholangiocarcinomas, whereas MUC2 and MUC5AC were focally and weakly expressed. MMP-2 and MMP-9 were strongly expressed in 22 (73%) of 30 human cholangiocarcinomas and 24 (100%) of 24 rat cholangiocarcinomas, respectively. p53 overexpression was detected in 9 (30%) of 30 human cholangiocarcinoma and none of the rat cholangiocarcinoma, respectively.

Conclusions: The expression of EGFR, apomucins, MMPs, and p53 in rat cholangiocarcinoma was strongly homologous to human cholangiocarcinoma. Thioacetamide-induced cholangiocarcinoma in rats provides an excellent model for investigating cholangiocarcinogenesis in vivo.

PubMed Disclaimer

Figures

None
FIGURE 1. Multiple mass-forming peripheral cholangiocarcinoma in Sprague-Dawley rat induced by thioacetamide 0.3% at 16 weeks.
None
FIGURE 2. Strong expression of epidermal growth factor receptor in rat (A) and human (B) cholangiocarcinoma, respectively (original magnification, 400×).
None
FIGURE 3. Strong expression of MUC1 in rat (A) and human (B) cholangiocarcinoma, respectively. Focal and weak expression of MUC2 in rat (C) and human (D) cholangiocarcinoma, respectively. Focal and weak expression of MUC5AC in rat (E) and human (F) cholangiocarcinoma, respectively (original magnification, 400×).
None
FIGURE 4. Strong expression of MMP-2 in rat (A) and human (B) cholangiocarcinoma, respectively. Strong expression of MMP-9 in rat (C) and human (D) cholangiocarcinoma, respectively (original magnification, 400×).
None
FIGURE 5. Negative p53 overexpression in rat cholangiocarcinoma (A); and strong p53 overexpression in human adenosquamous cholangiocarcinoma (B) (original magnification, 400×).
See this image and copyright information in PMC

References

    1. Chen MF, Jan YY, Wang CS, et al. Intrahepatic duct stone associated with cholangiocarcinoma. Am J Gastroenterol. 1989;84:391–395. - PubMed
    1. Chen MF, Jan YY, Wang CS, et al. A reappraisal of cholangiocarcinoma in patients with hepatolithiasis. Cancer. 1993;71:2461–2465. - PubMed
    1. Chen MF, Jan YY, Chen TC. Clinical studies of mucin-producing cholangiocellular carcinoma: a study of 22 histopathology-proven cases. Ann Surg. 1998;227:63–69. - PMC - PubMed
    1. Yeh TS, jan YY, Tseng JH, et al. Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol. 2000;95:432–440. - PubMed
    1. Jan YY, Yeh TS, Chen MF. Cholangiocarcinoma presenting as pyogenic liver abscess. Is its outcome influenced by concomitant hepatolithiasis? Am J Gastroenterol. 1998;93:253–255. - PubMed